Research programme: Polo-like kinase 1 inhibitors - Cyclacel

Drug Profile

Research programme: Polo-like kinase 1 inhibitors - Cyclacel

Alternative Names: CYC 800 series; CYC-140; CYC800; Plk1 inhibitors - Cyclacel; Polo-like kinase 1 inhibitors - Cyclacel; Research programme: cell cycle modulators - Cyclacel

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Mitosis inhibitors; Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 09 Jan 2018 Cyclacel intends to submit an IND application to the US FDA for CYC 140 for Cancer in 2018
  • 28 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Scotland (PO)
  • 04 Apr 2017 Pharmacodynamics data from a preclinical study in Cancer released by Cyclacel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top